IL151400A0 - Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use - Google Patents

Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Info

Publication number
IL151400A0
IL151400A0 IL15140001A IL15140001A IL151400A0 IL 151400 A0 IL151400 A0 IL 151400A0 IL 15140001 A IL15140001 A IL 15140001A IL 15140001 A IL15140001 A IL 15140001A IL 151400 A0 IL151400 A0 IL 151400A0
Authority
IL
Israel
Prior art keywords
peptidase
cleavable
therapeutic use
antineoplastic drugs
targeted antineoplastic
Prior art date
Application number
IL15140001A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of IL151400A0 publication Critical patent/IL151400A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15140001A 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use IL151400A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18938700P 2000-03-15 2000-03-15
PCT/US2001/008589 WO2001068145A2 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Publications (1)

Publication Number Publication Date
IL151400A0 true IL151400A0 (en) 2003-04-10

Family

ID=22697116

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15140001A IL151400A0 (en) 2000-03-15 2001-03-15 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use

Country Status (19)

Country Link
US (1) US6844318B2 (xx)
EP (1) EP1263473A2 (xx)
JP (1) JP2003526683A (xx)
KR (1) KR20030009388A (xx)
CN (1) CN1418112A (xx)
AU (2) AU4583601A (xx)
BR (1) BR0109266A (xx)
CA (1) CA2401873A1 (xx)
CZ (1) CZ20022998A3 (xx)
EE (1) EE200200522A (xx)
HU (1) HUP0300590A2 (xx)
IL (1) IL151400A0 (xx)
MX (1) MXPA02009019A (xx)
NO (1) NO20024238D0 (xx)
PL (1) PL360826A1 (xx)
RU (1) RU2002127425A (xx)
SK (1) SK12872002A3 (xx)
TR (1) TR200202183T2 (xx)
WO (1) WO2001068145A2 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095943A2 (en) 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
EP1545572A4 (en) * 2001-05-23 2006-04-12 Dendreon Corp CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF
EP1404356B1 (en) * 2001-06-11 2011-04-06 Medarex, Inc. Method for designing cd10-activated prodrug compounds
AU2002366303B2 (en) * 2001-12-17 2007-09-20 University College Cardiff Consultants Limited Enzymatic cleavable reagents for specific delivery to disease sites
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
JP4511805B2 (ja) * 2002-04-26 2010-07-28 武田薬品工業株式会社 ネプリライシンの活性測定法
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
FR2851471B1 (fr) * 2003-02-24 2006-07-28 Synt Em Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisations et lesdits agents de liaison
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US20100113328A1 (en) * 2003-05-29 2010-05-06 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
US20050137141A1 (en) * 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
KR101155740B1 (ko) 2004-03-31 2012-06-12 톳쿄기쥬츠 가이하츠 가부시키가이샤 상피계 세포증식 촉진제
JP2007099750A (ja) * 2005-02-25 2007-04-19 Hokkaido Univ 腫瘍組織で選択的に分解性を示す血中滞留性素子
WO2006124711A1 (en) * 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
US8962697B2 (en) * 2006-06-30 2015-02-24 Interface Biologics Inc. Bioreponsive polymers
EP1977765A1 (en) * 2007-04-03 2008-10-08 Diatos Peptide prodrugs
GB0707034D0 (en) * 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) * 2008-10-22 2008-11-26 Univ Bradford Compounds
ITUD20130024A1 (it) 2013-02-22 2014-08-23 Carlo Galli Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
WO2014145242A1 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Peptide-coated polymer carriers
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
CN111000988A (zh) * 2013-08-26 2020-04-14 健康研究公司 用于预防和/或治疗ErbB2阳性癌症的方法
EP3183342B1 (en) 2014-08-20 2021-05-12 Health Research, Inc. Method for prophylaxis and/or treatment of erbb1 positive cancers
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
MX2022000450A (es) * 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
MX2023007450A (es) 2020-12-21 2023-10-05 Univ Cornell Sistema de administración de fármacos ligados a péptidos.
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CN113876968B (zh) * 2021-10-29 2023-06-09 上海市第一人民医院 Mmp9响应的t1/t2切换型mr纳米探针及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
NZ291368A (en) 1994-08-19 1999-04-29 Wallone Region A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices
WO1997014416A1 (en) 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO1997048725A1 (en) 1996-06-21 1997-12-24 Peptech Limited Novel peptides for prevention and treatment of infection
WO1998010795A2 (en) 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
AU715632B2 (en) 1996-09-12 2000-02-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EP0964690B1 (en) 1996-10-15 2003-07-09 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
CA2286877A1 (en) 1997-04-14 1998-10-22 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
WO1999002175A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ES2342637T3 (es) 1998-12-11 2010-07-09 Medarex, Inc. Compuestos profarmacos y procedimiento para su preparacion.
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体
EP1181055A2 (en) * 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Enzyme-activated anti-tumor prodrug compounds
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds

Also Published As

Publication number Publication date
EP1263473A2 (en) 2002-12-11
WO2001068145A3 (en) 2002-07-11
CN1418112A (zh) 2003-05-14
EE200200522A (et) 2004-04-15
JP2003526683A (ja) 2003-09-09
MXPA02009019A (es) 2003-02-12
KR20030009388A (ko) 2003-01-29
RU2002127425A (ru) 2004-03-27
AU4583601A (en) 2001-09-24
TR200202183T2 (tr) 2007-01-22
CZ20022998A3 (cs) 2003-05-14
US20020103133A1 (en) 2002-08-01
NO20024238D0 (no) 2002-09-05
SK12872002A3 (sk) 2003-05-02
HUP0300590A2 (hu) 2003-07-28
US6844318B2 (en) 2005-01-18
AU2001245836A1 (en) 2002-07-16
PL360826A1 (en) 2004-09-20
CA2401873A1 (en) 2001-09-20
BR0109266A (pt) 2003-04-29
WO2001068145A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AU4583601A (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
HRP20040027A2 (en) 1-phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
HK1076110A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
HK1053118A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof.
HRP20010655B1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
EP1257255A4 (en) THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE
HU0002848D0 (en) Cyclobutene derivatives, their preparation and their therapeutic uses
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
HK1074444A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
AU2001243515A1 (en) Combination drug therapy
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
HK1063793A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
SI1161434T1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
SI1513835T1 (sl) Derivati piperazunilacilpiperidina, njihova priprava in njihova terapevtska uporaba
SI1513836T1 (sl) Derivati piperazinilacilpiperidina, njihova priprava in njihova terapevtska uporaba
GB0018687D0 (en) Multiple therapy drug delivery